New Ibrutinib (IMBRUVICA ®) Phase 2 Data Demonstrate Promise in Relapsed/Refractory Marginal Zone Lymphoma (MZL), a Rare, Incurable Type of Non-Hodgkin’s Lymphoma
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
More News: Lymphoma | Pharmaceuticals